Feature Selection
The predictor variables used by each published model, grouped into demographic, clinical, and radiological categories. Click any row for the full extraction record.
Showing 54 of 54 models
| Study | Year | Context | Outcome Predicted | Demographic | Clinical | Radiological |
|---|---|---|---|---|---|---|
| Schouten et al. | 2025 | Surveillance | Tumour Growth | — | — | MRI Radiomic Features: (1) Ktrans and (2) ve. |
| Stastna et al. | 2025 | Surveillance | Tumour Growth | Age Sex | — | Tumour Volume Hannover Grade Tumour Morphology (e.g. cystic) |
| Chen et al. | 2024 | Surveillance | Tumour Growth | — | — | Serial contrastenhanced T1 MRI volumes (3D tumour masks registered and cropped around the tumour) |
| Wang et al. | 2023 | Surveillance | Tumour Growth | — | — | MRI Radiomic Features (included features not specified) |
| Itoyama et al. | 2022 | Surveillance | Tumour Growth | Age | — | Tumour Length MRI Radiomics: Minimum signal intensity, inverse difference moment normalized (Idmn). |
| Hentschel et al. | 2021 | Surveillance | Tumour Growth | — | Balance complaints Tinnitus Time since onset of symptoms | Koos grade Intrameatal diameter |
| Varughese et al. | 2012 | Surveillance | Tumour Growth | — | — | Serial volumetric data |
| Timmer et al. | 2011 | Surveillance | Tumour Growth | — | Sudden sensorineural hearing loss Balance symptoms Short (<2 years) vs long duration (>2 years) hearing loss | Location (intrameatal vs extrameatal) |
| Cornelissen et al. | 2026 | Surveillance | Tumour Growth | — | — | Radiomic features (Baseline T2weighted MRI radiomics; DCEMRI radiomics from Ktrans, ve and vp parameter maps; tumour volume at diagnosis) |
| Gadot et al. | 2022 | Surveillance | Need for Intervention (SRS or Surgery) | Age Sex Hospital | New or progressive symptoms Recurrent tumour status Hydrocephalus Prior treatment Encounter number | Tumour location (IAC/CPA/IAC+CPA) Maximum tumour dimension Fundal cap Koos grade Brainstem involvement (“Koos_half”), brainstem compression (“Koos_worst”). |
| Bossi Zanetti et al. | 2023 | Stereotactic Radiosurgery | Tumour Growth | Age Sex | Symptoms Chronic disease Cranial nerve (V/VII) deficit Hearing grade Prior surgery | Tumour laterality intra/extracanalicular extent Total dose Fractionation Isodose. |
| George Jones et al. | 2021 | Stereotactic Radiosurgery | Tumour Growth | — | — | MRI Radiomic features: 55 radiomic features extracted via pyradiomics (v3.0): 13 shape features, 18 firstorder intensity features, 24 GLCM texture features. |
| Shi et al. | 2021 | Stereotactic Radiosurgery | Recurrence / Regrowth | — | Gene expression of collagen genes (COL5A1, COL3A1, COL4A1, COL15A1) | — |
| Yang et al. | 2021 | Stereotactic Radiosurgery | Regression vs Non-Response vs Pseudoprogression | — | — | 5 radiomic features extracted |
| Langenhuizen et al. | 2020 | Stereotactic Radiosurgery | Tumour Enlargement | — | — | MRI Radiomic features: firstorder statistics, Minkowski functionals (MFs), and threedimensional graylevel cooccurrence matrices (GLCMs). |
| Langenhuizen et al. | 2020 | Stereotactic Radiosurgery | Tumour Control | — | — | MRI Radiomic features • Firstorder statistics (20 features) • Minkowski functionals (4) • Graylevel cooccurrence matrices (GLCM, 4 features × param. variations) • Graylevel size zone matrix (GLSZM, 13 features) Extracted from T1, T1+C, and T2 MRIs. |
| Hildrew et al. | 2024 | Stereotactic Radiosurgery | Hearing Function | Age Sex | Baseline hearing status / AAOHNS hearing class; pure tone average; word recognition score; time since CK SRS | Maximum linear tumour dimension; tumour volume by 3D segmental volumetric analysis; fundal cap distance |
| Senova et al. | 2016 | Stereotactic Radiosurgery | Trigeminal Neuropathy | — | — | Tumour volume, AP diameter, SRS dosimetrics: (1) Volume of the cisternal portion o the Vth nerve receiving at least 11Gy (2) Volume of the cisternal portion of CN V and (3) maximum dose in the intraaxial portion (Gy) |
| Meeks et al. | 2000 | Stereotactic Radiosurgery | Facial or Trigeminal Neuropathy | — | — | Brainstem dose–volume histogram (DVH) parameters; maximum and mean brainstem dose; tumour and brainstem volume; partial brainstem volume irradiated; prescribed peripheral dose. |
| Fenton et al. | 2002 | Surgery | Post-op Facial Nerve Function | — | Intraoperative neuromonitoring (MIMAE) | Tumour size |
| Song et al. | 2025 | Surgery | Post-op Facial Nerve Function | — | — | Radiomic features extracted from preoperative 3DT2 and 3DFLAIR MRI: 107 features initially (shapebased, firstorder histogram, GLCM, GLDM, GLRLM, GLSZM, NGTDM) |
| Zohdy et al. | 2024 | Surgery | Post-op Facial Nerve Function | — | Proximaltodistal amplitude values from neuromonitoring channels (×5) | — |
| Fujita et al. | 2026 | Surgery | Post-op Facial Nerve Function | — | — | FFC sign, Subtype of CPA cisternal component, Cyst classification |
| Fujita et al. | 2025 | Surgery | Post-op Facial Nerve Function | — | — | Koos Grade Fundal Fluid Cap sign Morphological Subtype (Anterior vs Posterior) |
| Wang et al. | 2023 | Surgery | Post-op Facial Nerve Function | Age Sex BMI | Surgical strategy (not clarified) | Tumour diameter 13x Radiomic Features extracted from 4 MRI sequences (T1, T2, T1+C, T2FLAIR) CSF Cap sign |
| Shi et al. | 2024 | Surgery | Post-op Facial Nerve Function | — | — | Fundal Fluid Cap (FFC) sign Cerebrispinal Fluid Cleft (CSFC) sign Tumour size Expansion of IAC |
| Yu et al. | 2023 | Surgery | Post-op Facial Nerve Function & Degree of Tumour Resection | — | — | Tumour diameter (axial, sagittal, coronal), volume, surface area, Koos grade, Samii grade, tumour shape, cystic/solid property, brain tissue oedema (T2/FLAIR). |
| Heman-Ackah et al. | 2024 | Surgery | Post-op Facial Nerve Function | Age BMI | Case duration | Four tumour measurements (A–D) representing linear dimensions along the posterior petrous bone, porus acusticus and brainstem axes. |
| Wang J. et al. | 2022 | Surgery | Post-op Facial Nerve Function | Age Sex | Preoperative facial grade (HB I–VI); cerebellar symptoms (Y/N); posterior group neurological symptoms (Y/N) | Tumour size, tumour morphology (cystic/solid), brainstem compression, IAC shape, TFIAC grading, Samii grading |
| Isaacson et al. | 2003 | Surgery | Post-op Facial Nerve Function | — | Mean proximal threshold; proximaltodistal CMAP amplitude ratio | — |
| Przepiorka et al. | 2024 | Surgery | Post-op Facial Nerve Function | Age Sex Year of surgery | Shortterm facial nerve function; intraoperative difficulties; first symptom; preoperative ABR; preoperative Samii hearing scale; intraoperative use of nimodipine; duration of symptoms; tinnitus; dizziness; cerebellar signs; reason for diagnosis; histopathology; Samii grading scale; surgical position; postoperative complications; surgeon; hearing loss; neuromonitoring; preserved hearing after surgery; surgical approach; trigeminal nerve signs; preoperative headache; preoperative hydrocephalus; any previous treatment; preoperative House–Brackmann grade | Tumour volume (mm³) Facial nerve dislocation pattern Internal auditory canal (IAC) widening Tumour structure (solid vs cystic) |
| Harris et al. | 2024 | Surgery | Post-op Facial Nerve Function | — | Immediate postoperative HB grade; intraoperative facial nerve EMG response (≥100 µV vs <100 µV) | Maximum tumour diameter (≤25 mm vs >25 mm). |
| Ma et al. | 2025 | Surgery | Post-op Facial Nerve Function | Age, Gender | Preoperative House Brackman Grade, IONM (finaltobaseline amplitude ratio (FBR) of mentalis FNMEP) | — |
| Zohdy et al. | 2024 | Surgery | Post-op Facial Nerve Function | — | Proximaltodistal amplitude values from neuromonitoring channels (×5) | — |
| Di Perna et al. | 2023 | Surgery | Post-op Facial Nerve Function | — | Facial nerve IONM threshold; delta threshold | Tumour size Samii Classification Morphology (cystic vs solid) |
| Rivas et al. | 2011 | Surgery | Post-op Facial Nerve Function | — | Rate of postoperative facial nerve recovery; initial HB grade | Tumour Size |
| Fenton et al. | 2002 | Surgery | Post-op Facial Nerve Function | — | Immediate postoperative HB grade | — |
| Feghali et al. | 2025 | Surgery | Post-op Facial Nerve Function | — | Chronic Kidney Disease; Stimulation frequency at the end of surgery | Tumour Size (maximal diameter) |
| Lu et al. | 2024 | Surgery | Post-op Hearing Function | — | Preoperative PTA | Tumour Size Tumour Origin |
| Yang et al. | 2023 | Surgery | Post-op Hearing Function | Age | Hypertension; diabetes; other illnesses; symptom count; medication adherence; preoperative hearing class (AAOHNS) | Tumour position, size, cystic status, shape of internal auditory canal, Samii grade, TFIAC grade, |
| Dixon et al. | 2022 | Surgery | Post-op Hearing Function | Age, Sex, Ethnicity/Race, BMI, Smoking status, Marital and employment status | Hypertension; diabetes; sleep apnoea; mood disorder; migraine; preoperative symptoms (hearing loss, tinnitus, dizziness, facial symptoms); gait metrics (Dynamic Gait Index, Dizziness Handicap Inventory, walking speed) | Tumour size (transverse, AP, craniocaudal), Koos grade, growth rate, fundal CSF cap, tumour position relative to IAC midline (anterior/superior proportions). |
| Cha et al. | 2020 | Surgery | Post-op Hearing Function | — | Surgical approach; audiometric and vestibular function tests (PTA, WRS, SDT, MCL, ABR latency, VEMP asymmetry ratio, caloric canal paresis) | Largest diameter of the tumour |
| Dichter et al. | 2024 | Surgery | Unplanned Re-operation & Complications | Age Others not explicitly stated | Not explicitly stated – total of 110 pre, intra and postoperative variables (excluding radiological). Known examples: length of stay; days to discharge; time from preop bloods to operation; operative time; age; ASA class; hypertension; serum albumin | — |
| Suresh et al. | 2023 | Surgery | Post-op Dizziness | Age Sex | Preoperative headache; dizziness; hydrocephalus; CSF leak; House–Brackmann grade; completeness of resection; infection; need for physical therapy on discharge; vestibular medications; vestibular comorbidity; systemic comorbidities; surgical approach | Tumour Size (extrameatal diameter) |
| Tang et al. | 2022 | Surgery | In-hospital outcomes: mortality, perioperative complications, routine discharge, postoperative length of stay, total length of stay, and hospital costs. | Age | Preoperative cranial nerve palsies; diabetes; hypertension | Hydrocephalus |
| Smith et al. | 2021 | Surgery | Post-op Surgical Complications | Age, Sex, Ethnicity | Hearing loss (recent ≤2 years vs longstanding >2 years); vestibular dysfunction (Y/N); headache; tinnitus; facial numbness; comorbidity score (ACE27) | Tumour size category (< 1.5 cm, 1.5–2.5 cm, > 2.5 cm). |
| Macielak et al. | 2022 | Surgery | Extent of resection: GTR vs NTR/STR | Age | — | Tumour size (maximum extrameatal diameter, intracanalicular length, total diameter), fundal fluid cap sign |
| Zhang et al. | 2022 | Surgery | Recurrence Free Survival (need for further treatment or tumour regrowth >5mm) | Age | Extent of resection; Ki67 level | — |
| De Boer et al. | 2022 | Surgery | Post-op Tumour Recurrence | Age | — | Preoperative rate of tumour growth First postoperative MRI outcome |
| Song et al. | 2021 | Surgery | Intraoperative Tumour Vascularity | — | — | 12 radiomic texture features from T1WI, T2WI, T2FLAIR, and T1CE MRI sequences (e.g. GLCM, GLRLM, GLSZM, GLDMderived metrics). |
| Abouzari et al. | 2020 | Surgery | Self-reported tumour recurrence after treatment | — | Years since treatment; type of surgeon; resection amount (GTR vs STR/NTR); posttreatment complications (incomplete eye closure; dry eye; diplopia; facial pain; seizure; swallowing/voice problems) | — |
| Russel et al. | 2017 | Surgery | Post-op CSF leak | Age; sex | BMI; duration of surgery | — |
| Guan et al. | 2025 | Surgery | Post-op Facial Nerve Function | — | Intraoperative neuromonitoring; 3-month postoperative House–Brackmann grade | Tumour size; tumour morphology (cystic/solid) |
| Wei et al. | 2025 | Mixed management | Overall survival | Age; Sex; Race | Tumour size; Surgery; Radiation | — |